Boston Beer Reports Third Quarter Financial Results

Boston Beer’s Q3 2026 net revenue fell 3.2% to $520.1 million, while depletions declined 5% and shipments fell 4.9%; gross margin improved 90 basis points year over year to 51.7%. GAAP diluted EPS was $4.21, including $0.16 per share of non-recurring litigation expenses, versus non-GAAP EPS of $4.37. Year to date, the company reported a GAAP diluted loss of $4.87 per share, including $14.51 per share in non-recurring litigation expenses, and non-GAAP diluted EPS of $9.64; it ended the quarter with $308.1 million in cash, no debt, and had repurchased $79.5 million in shares since December 28, 2025.

Analysis

The key signal is persistent sell-through weakness, not the quarter’s adjusted EPS: shipments tracked depletions closely, so there is little evidence here that reported revenue was temporarily supported by channel loading—or that inventory normalization alone will repair the trend. Gross-margin expansion is a real buffer, but if volume and share keep eroding, cost or mix gains may only defer pressure on operating leverage.

For the next 1–3 months, watch subsequent depletion data and whether margin improvement survives promotional intensity and weaker volume. Over 6–18 months, sustained share loss would make the current margin resilience less durable and could constrain the value of repurchases. The buyback is a capital-allocation choice, not evidence of a demand inflection; valuation and remaining authorization are needed to judge its per-share benefit.

The large gap between GAAP and non-GAAP year-to-date EPS makes the litigation item a separate diligence issue: verify cash paid, remaining exposure, and whether management’s non-recurring characterization is supportable. No guidance, valuation, or post-release price action is provided, so the result alone does not establish that SAM is cheap or that the market has underreacted. A contrarian bullish case requires depletion stabilization, not just another quarter of margin expansion.

Key Decisions for Investors

• Keep SAM underweight versus beverage-alcohol peers pending evidence of improving depletions; consider adding only after sell-through stabilizes across successive reports. Falsify the cautious view if depletions turn positive without margin giveback.
• Do not trade the headline adjusted-EPS figure in isolation. Track depletions against shipments, gross margin, and promotional commentary in the next report; persistent volume weakness alongside margin compression would strengthen the downside case.
• Treat the litigation charge as a diligence alert, not automatically as harmless noise: verify cash impact and remaining exposure before assigning value to adjusted earnings.
• Avoid initiating a valuation-based short or options position without the share-price reaction, valuation, and implied volatility. If SAM materially outperforms on the release despite unchanged demand trends, reassess whether the market is pricing a recovery unsupported by sell-through.